Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02274389 · ClinicalTrials.gov registry record
A Prospective Patient Registry of Patients Exposed to Bedaquiline
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 5
- Enrollment target
NCT02274389 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 5 participants.
The verdict
NCT02274389 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to describe the medical indication and utilization of expert medical consultation among participants treated with bedaquiline (BDQ), BDQ susceptibility based on minimum inhibitory concentrations (MICs) reported for baseline and subsequent isolates, BDQ drug utilization data to include dose, duration, past treatment history, past medical history, concomitant medications, and health care site of treatment, drug distribution mechanisms used in the administration of BDQ, patient outcomes (clinical and microbiologic) and adverse events among BDQ-treated participants, including deaths.
Interventions
- DRUG No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-12-24 |
| Est. Completion | 2018-11-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02274389
The ClinicalTrials.gov registry entry for NCT02274389 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT02274389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02274389 about?
NCT02274389 is a clinical study titled "A Prospective Patient Registry of Patients Exposed to Bedaquiline". The purpose of this study is to describe the medical indication and utilization of expert medical consultation among participants treated with bedaquiline (BDQ), BDQ susceptibility based on minimum inhibitory concentrations (MICs) reported for baseline and subsequent isolates, BDQ drug utilization d...
What is the current status of trial NCT02274389?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2013-12-24. Estimated completion is 2018-11-20.
What interventions are being tested in trial NCT02274389?
The interventions under investigation include: No Intervention (DRUG).
Who is sponsoring clinical trial NCT02274389?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.